TCGA-56-6546-01A-11R-1820-07
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.520
- E2F_TARGETS+0.480
- MYC_TARGETS_V1+0.480
- G2M_CHECKPOINT+0.460
- ALLOGRAFT_REJECTION+0.420
- SPERMATOGENESIS+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- WNT_BETA_CATENIN_SIGNALING+0.230
- COMPLEMENT+0.220
- UV_RESPONSE_UP+0.190
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- PROTEIN_SECRETION-0.250
- ESTROGEN_RESPONSE_EARLY-0.230
- P53_PATHWAY-0.230
- FATTY_ACID_METABOLISM-0.220
- NOTCH_SIGNALING-0.220
- BILE_ACID_METABOLISM-0.210
- UV_RESPONSE_DN-0.210
- HEME_METABOLISM-0.200
- INTERFERON_ALPHA_RESPONSE-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A04T-01A-21R-A034-07 | — | E | 0.807 |
| 2 | BS_J1AB8PMA | medulloblastoma | — | 0.804 |
| 3 | SRR8942985 | — | — | 0.787 |
| 4 | TCGA-85-8276-01A-11R-2296-07 | — | cohortSQ1 | 0.782 |
| 5 | TCGA-OR-A5KZ-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.770 |
| 6 | DRR168611 | — | — | 0.761 |
| 7 | TCGA-68-8251-01A-11R-2296-07 | — | cohortSQ1 | 0.757 |
| 8 | SRR5088923 | — | — | 0.754 |
| 9 | TCGA-A1-A0SP-01A-11R-A084-07 | — | E | 0.741 |
| 10 | TCGA-77-A5GB-01B-11R-A27Q-07 | — | cohortSQ1 | 0.736 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.140 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |